Tiziana Life Sciences to Present Recent Clinical Updates at BIO-Europe in Munich, Germany, November 6-8, 2023
Tiziana Life Sciences (TLSA) announced that its Chief Operating Officer and Chief Medical Officer, Matthew Davis, will present at BIO-Europe in Munich, Germany. The presentation will focus on the clinical updates of intranasal foralumab for the treatment of diseases like multiple sclerosis and Alzheimer's. The company's management will also participate in one-on-one partnering meetings at the conference.
11/01/2023 - 07:00 AM
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced that its Chief Operating Officer and Chief Medical Officer, Matthew Davis, MD, RPh, will present at BIO-Europe, Munich, Germany, November 6-8, 2023. The presentation will be primarily focused on the recent clinical updates of intranasal foralumab, a fully human anti-CD3 monoclonal antibody, for the treatment of non-active secondary progressive multiple sclerosis and other neuroinflammatory and neurodegenerative diseases such as Alzheimer’s. Tiziana’s management will also be participating in one-on-one partnering meetings throughout the conference.
Presentation Information
Presenter: Matthew Davis, MD, RPh., Chief Operating Officer and Chief Medical Officer, Tiziana Life SciencesTitle: Intranasal Anti-CD3 mAb Therapy to Enable Breakthroughs in Neuroinflammatory and Neurodegenerative Diseases
Day: Wednesday, November 8thTime: 10:00 – 10:15 CETLocation: Room San Sebastian
BIO-Europe convenes over 5,500 attendees, representing 60 countries and 2,220+ companies, making the event the industry's largest gathering of biopharma professionals in Europe.
About Foralumab
Activated T cells play an important role in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), binds to the T cell receptor and dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune cell subsets. This effect has been demonstrated in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects. The non-active SPMS intranasal foralumab Phase 2 trial is expected to start screening in November of 2023. Immunomodulation by nasal anti-CD3 mAb represents a novel avenue for treatment of neuroinflammatory and neurodegenerative human diseases.1 , 2
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For further inquiries:
Tiziana Life Sciences Ltd
Paul Spencer, Business Development and Investor Relations info@tizianalifesciences.com
Investors: ikoffler@lifesciadvisors.com
_________________
1 https://www.pnas.org/doi/10.1073/pnas.22202721202 https://www.pnas.org/doi/10.1073/pnas.2309221120
What is the company name presenting at BIO-Europe?
The company presenting at BIO-Europe is Tiziana Life Sciences (TLSA).
Who will be presenting at BIO-Europe?
The Chief Operating Officer and Chief Medical Officer of Tiziana Life Sciences, Matthew Davis, will be presenting at BIO-Europe.
What will the presentation focus on?
The presentation will focus on the clinical updates of intranasal foralumab, a treatment for diseases like multiple sclerosis and Alzheimer's.
What other activities will Tiziana Life Sciences participate in at the conference?
Tiziana Life Sciences' management will also participate in one-on-one partnering meetings at the conference.
